XOMA Virtual Fireside Chat with H.C. Wainwright & Co.

Virtual, July 20, 2021

Join XOMA Corporation for a virtual fireside chat with Joseph Pantginis, Ph.D, of H.C. Wainwright & Co., discussing the royalty aggregator model and what’s next for XOMA. XOMA monetizes and aggregates royalty payment rights associated with pre-commercial drug candidates with a focus on development-stage assets with blockbuster potential that are licensed to well-capitalized partners. They use a portfolio approach to acquire new assets, thereby mitigating single-asset binary exposure.


Joseph Pantginis, Ph.D.H.C Wainwright & Co., Managing Director of Equity Research

James Neal, XOMA, Chief Executive Officer and member of the Board

Thomas Burns, XOMA, Senior Vice President, Finance and Chief Financial Officer

RSVP Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

XOMA Corporation [XOMA] $206 MM MCap
Biotech roy­al­ty and mile­s­tone ag­gre­ga­tor with port­fo­lio of 70+ as­sets in >30 dis­closed in­di­ca­tions where R&D costs are borne by part­n­ers e.g. Roche's Faricimab (BLA filed for nAMD and DME 7/29/21) [more in­for­ma­tion]